MedTech Magazine, December 2018
When it comes to pulmonary drug administration and therapy adherence, it is noted that many of the commercially available inhalers such as Dry Powder Inhalers (DPIs) and Metered Dose Inhalers (MDIs) are relatively limited in their effectiveness. In this article, Maurits Huigen explains why and how Gilbert solves the limiting effects of current inhalers with a new finding using an electrospraying technique.
Read the full article published on Med Tech Outlook.
Gilbert is developing the next generation of soft mist inhalers based on a proprietary electrospray (Electro Hydrodynamic Atomization or EHDA) technology to redefine treatment for lung patients. Gilbert’s breath actuated smart precision inhaler creates a monodispersed soft mist aerosol, with a customizable droplet size enabling more precise targeting of drugs to desired regions of the lungs, which has the potential to improve the efficacy and safety of treatments. Electrospray enables gentle, efficient delivery of both small and large molecule therapies in both solution and suspension formulations.
Visit us at Gilbert | Redefining treatment for lung patients, follow us on Linkedin or contact us at info@gilbert.eu to learn if electrospray is suitable for your application.
Stay up-to-date with Gilbert’s latest news, vacancies and achievements by following us on social media.